Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
-0.27%63.771.4%$1739.02m
JNJJohnson & Johnson
0.07%141.440.7%$876.14m
PFEPfizer Inc.
-0.55%38.330.9%$729.42m
MRKMerck & Co., Inc.
0.32%89.240.7%$685.29m
ABBVAbbVie, Inc.
-1.07%87.782.3%$607.65m
LLYEli Lilly & Co.
-0.14%121.531.1%$364.17m
NVSNovartis AG
0.25%93.290.2%$151.08m
AZNAstraZeneca Plc
0.92%48.361.2%$138.40m
GSKGlaxoSmithKline Plc
0.13%45.990.2%$137.93m
SNYSanofi
0.57%49.790.2%$114.51m
RETAReata Pharmaceuticals, Inc.
2.84%206.753.5%$108.66m
KRTXKaruna Therapeutics, Inc.
-11.24%65.250.0%$105.65m
NVONovo Nordisk A/S
1.33%57.250.1%$92.18m
ALLKAllakos, Inc.
-2.21%123.190.0%$74.02m
FTSVForty Seven, Inc.
-7.72%35.750.0%$50.91m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.